Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Viscosupplementation with High Molecular Weight Hyaluronic Acid for Hip Osteoarthritis: a Systematic Review and Meta-Analysis of Randomised Control Trials of the Efficacy on Pain, Functional Disability, and the Occurrence of Adverse Events [Viskosuplementace vysokomolekulární kyselinou hyaluronovou pro kyčelní osteoartrózu: systematický přehled a metaanalýza randomizovaných kontrolních studií účinnosti na bolest, funkční postižení a výskyt nežádoucích účinků]

R. Patel, G. Orfanos, W. Gibson, T. Banks, G. McConaghie, R. Banerjee

. 2024 ; 91 (2) : 109-119. [pub] -

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, systematický přehled, metaanalýza

Perzistentní odkaz   https://www.medvik.cz/link/bmc24009795

PURPOSE OF THE STUDY: Hip osteoarthritis (OA) has a prevalence of around 6.4% and is the second most commonly affected joint. This review aims to assess the clinical outcomes of intra-articular high molecular weight hyaluronic acid (HMWHA) in the management of hip osteoarthritis. MATERIAL AND METHODS: We conducted a comprehensive search across PubMed, Google Scholar, and the Cochrane Library for randomised trials investigating the effectiveness of high molecular weight hyaluronic acid (HMWHA) in the treatment of hip osteoarthritis. Quality and risk of bias assessments were performed using the Cochrane RoB2 tool. To synthesise the data, we utilised the Standardised Mean Difference (SMD) for assessing pain relief through the Visual Analogue Scale (VAS) and the Lequesne index (LI) for evaluating functional outcomes. Risk Ratio (RR) was calculated to assess the occurrence of complications. RESULTS: A total of four studies involving HMWHA and control groups were included. The standardised mean difference (SMD) for the Visual Analogue Scale (VAS) (SMD -0.056; 95% CI; -0.351, 0.239; p = 0.709) and the Lequesne index (SMD -0.114; 95% CI; -0.524, 0.296; p = 0.585) were not statistically significant. Analysis for complications demonstrated an overall relative risk ratio (RR) of 0.879 (95% CI; 0.527, 1.466; p = 0.622), and was not statistically significant. DISCUSSION AND CONCLUSIONS: Intra-articular HMWHA in hip OA can significantly reduce pain and improve functional recovery when compared with the condition before treatment. However, there is no significant difference between HMWHA, or saline, or other therapeutic treatments. Currently, available evidence indicates that intra-articular HMWHA in hip OA would not increase the risk of adverse events. KEY WORDS: hip osteoarthritis, hyaluronic acid, intra-articular, molecular weight, viscosupplementation.

Viskosuplementace vysokomolekulární kyselinou hyaluronovou pro kyčelní osteoartrózu: systematický přehled a metaanalýza randomizovaných kontrolních studií účinnosti na bolest, funkční postižení a výskyt nežádoucích účinků

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24009795
003      
CZ-PrNML
005      
20250402155234.0
007      
ta
008      
240606s2024 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.55095/ACHOT2024/009 $2 doi
035    __
$a (PubMed)38801667
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Patel, R. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom $u Department of Trauma and Orthopaedics, The Princess Royal Hospital, Telford, United Kingdom $u Department of Trauma and Orthopaedics, Royal Shrewsbury Hospital, Shrewsbury, United Kingdom
245    10
$a Viscosupplementation with High Molecular Weight Hyaluronic Acid for Hip Osteoarthritis: a Systematic Review and Meta-Analysis of Randomised Control Trials of the Efficacy on Pain, Functional Disability, and the Occurrence of Adverse Events / $c R. Patel, G. Orfanos, W. Gibson, T. Banks, G. McConaghie, R. Banerjee
246    31
$a Viskosuplementace vysokomolekulární kyselinou hyaluronovou pro kyčelní osteoartrózu: systematický přehled a metaanalýza randomizovaných kontrolních studií účinnosti na bolest, funkční postižení a výskyt nežádoucích účinků
520    9_
$a PURPOSE OF THE STUDY: Hip osteoarthritis (OA) has a prevalence of around 6.4% and is the second most commonly affected joint. This review aims to assess the clinical outcomes of intra-articular high molecular weight hyaluronic acid (HMWHA) in the management of hip osteoarthritis. MATERIAL AND METHODS: We conducted a comprehensive search across PubMed, Google Scholar, and the Cochrane Library for randomised trials investigating the effectiveness of high molecular weight hyaluronic acid (HMWHA) in the treatment of hip osteoarthritis. Quality and risk of bias assessments were performed using the Cochrane RoB2 tool. To synthesise the data, we utilised the Standardised Mean Difference (SMD) for assessing pain relief through the Visual Analogue Scale (VAS) and the Lequesne index (LI) for evaluating functional outcomes. Risk Ratio (RR) was calculated to assess the occurrence of complications. RESULTS: A total of four studies involving HMWHA and control groups were included. The standardised mean difference (SMD) for the Visual Analogue Scale (VAS) (SMD -0.056; 95% CI; -0.351, 0.239; p = 0.709) and the Lequesne index (SMD -0.114; 95% CI; -0.524, 0.296; p = 0.585) were not statistically significant. Analysis for complications demonstrated an overall relative risk ratio (RR) of 0.879 (95% CI; 0.527, 1.466; p = 0.622), and was not statistically significant. DISCUSSION AND CONCLUSIONS: Intra-articular HMWHA in hip OA can significantly reduce pain and improve functional recovery when compared with the condition before treatment. However, there is no significant difference between HMWHA, or saline, or other therapeutic treatments. Currently, available evidence indicates that intra-articular HMWHA in hip OA would not increase the risk of adverse events. KEY WORDS: hip osteoarthritis, hyaluronic acid, intra-articular, molecular weight, viscosupplementation.
650    _2
$a lidé $7 D006801
650    12
$a kyselina hyaluronová $x terapeutické užití $x škodlivé účinky $7 D006820
650    12
$a artróza kyčelních kloubů $x farmakoterapie $x komplikace $7 D015207
650    12
$a randomizované kontrolované studie jako téma $7 D016032
650    12
$a viskosuplementace $x metody $7 D055676
650    12
$a viskosuplementy $x aplikace a dávkování $x terapeutické užití $7 D055675
650    _2
$a injekce intraartikulární $7 D007270
650    _2
$a měření bolesti $7 D010147
650    _2
$a molekulová hmotnost $7 D008970
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
655    _2
$a metaanalýza $7 D017418
700    1_
$a Orfanos, G. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
700    1_
$a Gibson, W. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
700    1_
$a Banks, T. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
700    1_
$a McConaghie, G. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
700    1_
$a Banerjee, R. $u Department of Trauma and Orthopaedics, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
773    0_
$w MED00011021 $t Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca $x 0001-5415 $g Roč. 91, č. 2 (2024), s. 109-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38801667 $y Pubmed
910    __
$a ABA008 $b A 8 $c 507 $y p $z 0
990    __
$a 20240606 $b ABA008
991    __
$a 20250402155230 $b ABA008
999    __
$a ok $b bmc $g 2294524 $s 1219625
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 91 $c 2 $d 109-119 $e - $i 0001-5415 $m Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca $n Acta Chir Orthop Traumatol Cech $x MED00011021
LZP    __
$b NLK124 $a Pubmed-20240606

Najít záznam

Citační ukazatele

Možnosti archivace